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Background: Emerging and epidemic infectious disease outbreaks are a significant public health problem and
global health security threat. As an outbreak begins, epidemiological investigations and traditional public health
responses are generally mounted very quickly. However, patient-centred research is usually not prioritised when
planning and enacting the response. Instead, the clinical research response occurs subsequent to and separate
from the public health response, and is inadequate for evidence-based decision-making at the bedside or in the
offices of public health policymakers.
Discussion: The deficiencies of the clinical research response to severe acute respiratory syndrome, pandemic
influenza, Middle East respiratory syndrome coronavirus and Ebola virus demonstrate that current research models
do not adequately inform and improve the quality of clinical care or public health response. Three suggestions
for improvements are made. First, integrate the data and sample collection needs for clinical and public health
decision-making within a unified framework, combined with a risk-based, rather than a discipline-based, approach
to ethical review and consent. Second, develop clinical study methods and tools that are specifically designed to
meet the epidemiological and contextual challenges of emerging and epidemic infectious diseases. Third, invest in
investigator-led clinical research networks that are primed and incentivised to respond to outbreak infections, and
which can call on the support and resources of a central centre of excellence.
Conclusions: It is crucial that the field of epidemic science matures to place patients at the heart of the response.
This can only be achieved when patient-centred research is integrated in the outbreak response from day one and
practical steps are taken to reduce the barriers to the generation of reliable and useful evidence.
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Emerging and epidemic infectious diseases (EEIDs) have
shaped society, and recent events affirm that they will
continue to do so. In less than two years, Ebola virus
disease (EVD) and the Zika virus prompted the World
Health Organization (WHO) to declare Public Health
Emergencies of International Concern. Meanwhile,
Middle East respiratory syndrome coronavirus (MERS-
CoV) continues to cause sporadic cases and nosocomial
outbreaks, and an increasing diversity of avian influenza
viruses are infecting people across numerous continents* Correspondence: peter.horby@ndm.ox.ac.uk
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Health Risk Framework for the Future estimating that
the annual cost of a potential pandemic is around US
$60 billion [3], epidemic infectious diseases remain a
force to be reckoned with [4].
Preparing ourselves adequately for these threats
demands action on many fronts, including the strength-
ening of health systems, improved surveillance and
response capabilities, and better pipelines for developing
diagnostics, therapeutics and vaccines. ‘Patient-centred’
research needs to be included as one key pillar of an
enhanced outbreak investigation, response and control
system. Patients are the primary source of much of the
information (e.g. clinical presentation and outcomes)
and materials (e.g. pathogens and antibodies) that is vital
for both clinical and public health decision-making;
for advancing basic scientific understanding; and forle is distributed under the terms of the Creative Commons Attribution 4.0
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and vaccine development pipelines. We argue that
our thinking should therefore converge on the patient
and we should address the needs of all disciplines
within a strengthened and unified framework.
The importance of patient-centred research during
epidemics
Improving patient outcomes
In the turmoil of epidemics and the pressure to protect
public health and economic interests, it is sometimes
forgotten that patients lie at the heart of every outbreak.
These patients, their families and the clinical teams
caring for them are often struggling with frightening
uncertainty and inadequate support and resources. How-
ever, during epidemics, decisions such as which drugs,
fluids or supportive care strategies to offer patients are
usually made on an ad hoc basis by the treating clinician,
or from guidelines that approximate from other diseases
and experiences [5, 6]. The African trial of Fluid Expan-
sion As Supportive Therapy (FEAST) for critically ill
children, which found that giving fluid boluses to
severely ill children with impaired perfusion in resource-
limited settings in Africa actually increased mortality,
was a clear demonstration of the potential dangers of
plausible extrapolation [7]. All patients, irrespective of
the location and circumstances of their illness, deserve
evidence-based care. Yet, when we examine recent
notable outbreaks including severe acute respiratory
syndrome (SARS), avian influenza, pandemic influenza,
MERS-CoV and EVD, very few patients have benefited
from clinical research. Indeed we have yet to identify an
effective therapeutic agent for any of these infections.
Whilst the neuraminidase inhibitors (e.g. oseltamivir)
have demonstrated efficacy in shortening symptom
duration in uncomplicated influenza and as prophylactic
agents, uncertainty remains as to their effectiveness in
preventing and treating severe influenza [8–10]. Despite
almost 800 avian influenza A/H7N9 cases since 2013,
there is only one registered treatment trial on clincial-
trials.gov (NCT02095444). This represents a major
global vulnerability, given that both the probability and
impact of an influenza pandemic are high, and pandemic
influenza vaccines cannot yet be produced in a time-
frame to impact the first wave of the pandemic. There
are also only two clinical treatment trials registered for
MERS Co-V (NCT02845843, NCT02190799), although
cases have now been reported for 4 years. SARS provides
an excellent example of the consequences of an inad-
equate clinical research response. The antiviral ribavirin
was widely used during the early outbreak owing to its
broad action and prior experience with its use for other
indications. As the epidemic progressed, small case
series and emerging in vitro data suggested poor efficacyand tolerability, and so use of this agent declined [11].
However, retrospective review of these series indicated
they had significant methodological limitations [12], and
if another SARS outbreak was to occur there remains no
clear consensus on ribavirin use. There has also been a
failure to gather evidence on the effectiveness of readily
available and widely used supportive care measures. For
example, when treating EVD there remains no robust
evidence on the optimal intravenous fluid resuscitation
strategy, the use of vitamin K, or the provision of lopera-
mide for diarrhoea, all practices that were adopted to
varying extents during the West Africa (2013–2016)
epidemic.
Helping to control the epidemic
Patients with epidemic and emerging infections deserve
to benefit from the fruits of research as much as any
other patient, yet the broader societal benefits of clinical
research are even greater in the context of outbreaks. A
well-focused and calibrated public health response to an
epidemic can save lives and money. The West Africa
Ebola epidemic is set to become a notorious case study
of the consequences of under-reaction, whereas the early
response to the 2009 A/H1N1 influenza pandemic is
widely considered to have been an over-reaction [13].
Many aspects of an appropriate public health response
are dependent on high-quality data and samples from
patients. For example, reliable illness severity data are
required to predict the number of infected and ill people
and then scale the response appropriately; groups at high
risk for infection or poor prognosis need to be identified
for targeted preventative and treatment interventions;
genetic sequencing of pathogens from biological samples
can provide critical information on transmission path-
ways, evolutionary pressures and drug resistance; and
the characterisation of immunological responses is a
prerequisite for developing the laboratory tools for
critical sero-epidemiologic and vaccine immunogenicity
studies. Figure 1 summarises the public health value of
some of the key parameters that can only be derived from
patients.
Even when faced with an outbreak of what we think is
a well-characterised infection, there is always a need to
critically re-evaluate received wisdom and to be sceptical
of initial impressions. Influenza is a good case in point.
The initial public health response to the 2009 influenza
A/H1N1 pandemic is widely considered to have been
poorly calibrated owing to excessive early estimates of
the case fatality rate based on data from Mexico City
and Winnipeg [14, 15]. What was initially thought to be
a severe novel influenza turned out to be no more severe
than an average seasonal influenza [16]. The resulting
expenditure on antivirals and vaccines has been widely
criticised and illustrates the social and economic
Fig. 1 The public health value and impact of patient-centred assessments
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severity that explicitly considers biases that are inherent
in surveillance and reporting systems.
As a result of the limited availability of systematically
collected natural history data for EVD, it has only
recently been established that fever is absent in approxi-
mately 10% of patients [17, 18]. However, fever was used
for the entirety of the West Africa epidemic as often the
solitary indicator for screening at airports and check-
points, and as part of the case definition for Ebola virus
testing [19, 20]. Limitations in collecting and analysing
biological specimens from patients have resulted in inad-
equate understanding of transmission risks. For example,
despite 22 prior EVD outbreaks and around 2000 cases,
it was also only in 2015 that the risk of sexual transmis-
sion was confirmed [21]. There have been few, if any,
comparable and comprehensive sampling studies done
for other high-threat epidemic-prone diseases, even
those with predictable seasonal outbreaks such as
Crimean-Congo haemorrhagic fever. During the most
recent Public Health Emergency of International Con-
cern, the Zika virus outbreak, the poor availability of
well-characterised patient-derived samples has impeded
the development and validation of crucial assays for
patient diagnosis [22].
It is clear that there is significant room for im-
provement in the systematic collection of data and
biological samples from patients with the explicit aim
of improving the evidence-base for public health
decision-making.How do we make progress?
Integrated clinical data capture
Currently, outbreak response is characterised by an arti-
ficial separation of the public health, clinical and scien-
tific response. This is an understandable consequence of
engrained disciplinary divisions and regulatory frame-
works but is inefficient given that the ultimate aims of
all groups are to improve patient outcomes and control
the epidemic. Under even a cursory examination, it is
clear that the boundaries between the public health, clin-
ical and scientific response are blurred, with the neces-
sary evidence overlapping and being collected from the
same patient. What distinguishes research from clinical
or public health practice is often difficult to define, and
rather than trying to draw arbitrary boundaries, we
should aim to integrate the data needs of all disciplines.
The quality of evidence could then be improved by de-
signing unified data and sample collection protocols that
are driven by an explicit link to the public health and
clinical decisions that need to be taken. Rather than
using inferential techniques such as mathematical mod-
elling to compensate for suboptimal data, analysis-ready
datasets that provide meaningful information to support
individual and population-based practices could be gen-
erated by working forwards from a suite of public health
and clinical decisions, to evidence needs, and finally to
data needs (Fig. 2). The goal of such a decision-driven
data collection approach is to identify the most efficient
way to improve the precision and timeliness of pivotal es-
timates such as attack rate, case-fatality rate, transmission
Fig. 2 A schematic for interdisciplinary decision-driven data and sample collection
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viding the data elements that are needed for bedside
clinical decision-making. This approach should include
prior consideration of the impact of missing data and
sampling biases on the validity, accuracy, and precision of
estimates.
Whilst it would be naïve to think there are template
data capture tools or protocols that will perfectly fit any
outbreak, it would be a major step forward if data cap-
ture instruments were to be developed that are explicit
about the content, quality and scale of data needed to
take decisions, combined with a risk-based, rather than a
discipline-based, approach to the need for ethical review
and consent. Because outbreaks involve a complex inter-
action between the rights, responsibilities, benefits and
risks of both individuals and communities, there will
often be a need for careful community engagement and
for ethical review by committees that are well versed in
the specific ethical issues raised by epidemics [23].
New clinical study methodologies and tools
There is no doubting that epidemics are a challenging
context in which to conduct research, but that just
means we must adapt, not abandon, our research ap-
proach. Significant improvements in the care provided
for patients treated for battlefield trauma [24] and in
pre-hospital settings [25, 26] over the last few decades
demonstrate that it is feasible to conduct patient-centred
research in austere and challenging environments. The
biggest remaining challenge for clinical research on
EEIDs is uncertainty: emerging infections are often rela-
tively rare; understanding of the clinical presentation
and natural history is usually limited; and outbreaks are
unpredictable in timing, location and size. Classical
clinical trial designs that require predictable and often
large case numbers to test hypotheses are not well suited
to this epidemiological uncertainty. Trial designs are
needed that are robust to uncertainties in the number,
timing and location of cases; clinical phenotype, progres-
sion and outcomes; the optimal comparison (control)group; and the optimal intervention to test. The West
Africa Ebola outbreak stimulated some innovative think-
ing in the design of clinical trials [27, 28] and this needs
to continue. It should encompass designs for descriptive
clinical studies, and prophylactic, therapeutic and vac-
cine trials under a variety of epidemiological scenarios.
The successful implementation of protocols for inte-
grated clinical data collection and of novel clinical trials
will require action to lower the barriers to the collection
and sharing of standardised data. Such action should in-
clude the development of standardised data libraries and
therapeutic area standards for epidemic infections (using
the Clinical Data Standards Consortium system, cdis-
c.org); designing and evaluating generic disease severity
scores and outcome measures; and the development of
user-friendly, scalable and open-access software for data
capture and sharing (including the use of federated
databases).
Strengthened global coordination and support for clinical
research on EEIDs
It is worth considering the substantial difficulties that
face those who wish to undertake clinical research on
emerging and epidemic infections. First, many emerging
pathogens might be considered rare. The European def-
inition of a ‘rare disease’ is a disease that affects fewer
than 1 in 2000 people, whereas the US definition is a
disease that affects fewer than 200,000 citizens [29]. The
diseases currently under the ‘rare diseases’ umbrella are
largely severe non-communicable diseases with a genetic
component, such as cystic fibrosis, or rare cancers.
Although direct comparison of infectious epidemic
diseases and rare non-infectious diseases is somewhat
artificial, it can nevertheless be illustrative. SARS
resulted in a total of 8096 cases [30]; 850 cases of avian
influenza A/H5N1 have been reported since 2003 [31];
684 cases of avian influenza A/H7N9 have been reported
since March 2013; and 1733 MERS-CoV cases have been
reported since September 2012 [32]. For comparison
there are an estimated 14,000 people living with
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Ewing sarcoma annually in the US alone. Second, the
timeframe for action can be both unpredictable and
extremely short, with the average duration of influenza
epidemics being 10 weeks, with the peak incidence
reached after only 4 weeks [33]. Third, the spatial distri-
bution can be widespread. The 660 patients diagnosed
with avian influenza A/H7N9 in China between March
2013 and September 2015 were admitted to 258 different
hospitals, an average of under one patient per hospital
per year (personal communication, Yu Hongjie, China
CDC). The 854 H5N1 cases reported since 2004 have
arisen in 16 different countries [34].
The bottom line is that the unpredictability, rapidity and
rarity of many emerging infectious disease outbreaks
render it improbable that a meaningful research response
can be delivered by isolated investigators or institutions.
Large-scale international collaboration is essential. In the
wake of the West Africa Ebola outbreak, several initiatives
have highlighted and attempt to address key deficiencies
in our ability to respond to major infectious disease out-
breaks. These include the newly established WHO Health
Emergencies Programme, the WHO R&D Blueprint for
Action to Prevent Epidemics, the report of the Commis-
sion on a Global Health Risk Framework for the Future,
and the Coalition for Epidemic Preparedness Innovations.
However, none of these initiatives specifically or ad-
equately address the weaknesses of platforms for conduct-
ing essential clinical research both before and during
outbreaks. This renewed interest in global health security
and in research and development for epidemic infections
is to be welcomed but must be accompanied by invest-
ment in a sustainable operating model for EEID clinical
research networks. Otherwise the clinical research plat-
forms and tools that are needed to rapidly characterise
emerging infectious threats and to evaluate the products
of diagnostic, drug and vaccine development pipelines
will, once again, not be there when we need them.
One of the earliest clinical research networks with a spe-
cific focus on EEIDs was the South-East Asia Infectious
Diseases Clinical Research Network (SEAICRN), which
was established in response to the re-emergence of avian
influenza A/H5N1 in 2003. Following from SEAICRN, the
International Severe Acute Respiratory and Emerging
Infections Consortium (ISARIC) was established in 2012
as a global investigator-led network-of-networks aiming to
‘foster global collaborative patient-oriented research be-
tween and during epidemics’ [35]. ISARIC members have
subsequently been prominent in the development of two
further regional clinical research networks focused on
preparedness for emerging and epidemic infections: the
European Commission-funded Platform for European Pre-
paredness Against (Re-) emerging Epidemics (PREPARE)
and the Australian Partnership for Preparedness Researchon Infectious Disease Emergencies (APPRISE). These
networks have made significant contributions to building
capacity [36], linking researchers, developing tools such as
syndrome-based clinical characterisation and generic treat-
ment trial protocols [35, 37, 38], identifying ethical and
legal barriers [39], and responding to outbreaks [40–48].
However, sustaining and coordinating EEID clinical re-
search networks is a major challenge when both disease
incidence and funding are unpredictable and fluctuating.
It simply is not realistic to establish and maintain epi-
demic clinical research capabilities in every centre where
an outbreak might occur. This is particularly true in
areas where poverty and inadequate healthcare systems
mean that despite increased vulnerability to epidemic in-
fections there are far more pressing day-to-day priorities.
This does not mean that the only answer is to parachute
researchers into an affected area. A model that has
worked well for rare non-communicable diseases is the es-
tablishment of Rare Diseases Clinical Research Consortia,
which are supported by a Rare Diseases Data Management
and Coordination Center. This may be a good model for
EEIDs, where geographic or disease-specific clinical re-
search networks working on day-to-day infectious diseases
problems (including drug-resistant infections) are primed
and incentivised to respond to outbreak infections, and
are supported by a centre of excellence that houses the ex-
pertise and resources required to develop and test new
methods and tools, to coordinate or lead multi-centre re-
search on EEIDs, and to provide much needed support
and tools to local investigators in the event of an
emergency. This might be conceptualised as a multiple
hub-and-spoke, or dandelion, model, where each research
network has its own hub, but each hub can call on the
support and resources of a central centre of excellence.Summary
The response to epidemics has been plagued with poor
data and weak evidence, and the central importance of
patient-based clinical research is widely underappreciated.
We risk continuing to fail the patients and communities
most affected unless we work towards an improved frame-
work. Key features of this improved framework
include integrating patient-centred research with other
aspects of outbreak response, developing methods and
tools that address the very real epidemiological and
contextual challenges of EEIDs, and building an
organisational model for clinical research on EEIDs
that is effective and sustainable.Abbreviations
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